×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KNSA – kiniksa pharmaceuticals, ltd. - class a ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KNSA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
04:01 pm
knsa
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
Low
Report
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
11/5
11:19 am
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at JPMorgan Chase & Co. from $39.00 to $40.00. They now have an "overweight" rating on the stock.
Low
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at JPMorgan Chase & Co. from $39.00 to $40.00. They now have an "overweight" rating on the stock.
10/30
11:28 am
knsa
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at Evercore ISI from $30.00 to $35.00. They now have an "outperform" rating on the stock.
Low
Report
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at Evercore ISI from $30.00 to $35.00. They now have an "outperform" rating on the stock.
10/29
07:30 am
knsa
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
High
Report
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
10/28
10:45 am
knsa
Here's What Could Help Kiniksa Pharmaceuticals (KNSA) Maintain Its Recent Price Strength [Yahoo! Finance]
Low
Report
Here's What Could Help Kiniksa Pharmaceuticals (KNSA) Maintain Its Recent Price Strength [Yahoo! Finance]
10/28
08:00 am
knsa
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
Low
Report
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
10/22
04:01 pm
knsa
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
Low
Report
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
10/11
10:40 am
knsa
What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing' [Yahoo! Finance]
Low
Report
What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing' [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/29/2024
07:30 am
KNSA
kiniksa pharmaceuticals, ltd. - class a ordinary shares
MISS
Report
-15.7%
kiniksa pharmaceuticals, ltd. - class a ordinary shares
7/23/2024
07:30 am
KNSA
kiniksa pharmaceuticals, ltd. - class a ordinary shares
BEAT
Report
17.1%
kiniksa pharmaceuticals, ltd. - class a ordinary shares
4/23/2024
07:30 am
KNSA
kiniksa pharmaceuticals, ltd. - class a ordinary shares
MISS
Report
-2.3%
kiniksa pharmaceuticals, ltd. - class a ordinary shares
2/28/2024
07:30 am
KNSA
kiniksa pharmaceuticals, ltd. - class a ordinary shares
BEAT
Report
-2.5%
kiniksa pharmaceuticals, ltd. - class a ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:33 pm
knsa
Form SC 13G/A Kiniksa Pharmaceuticals Filed by: HHLR ADVISORS, LTD.
Low
Report
Form SC 13G/A Kiniksa Pharmaceuticals Filed by: HHLR ADVISORS, LTD.
11/14
04:16 pm
knsa
Form SC 13G/A Kiniksa Pharmaceuticals Filed by: Fairmount Funds Management LLC
Low
Report
Form SC 13G/A Kiniksa Pharmaceuticals Filed by: Fairmount Funds Management LLC
11/13
04:31 pm
knsa
Form SC 13G/A Kiniksa Pharmaceuticals Filed by: Rubric Capital Management LP
Medium
Report
Form SC 13G/A Kiniksa Pharmaceuticals Filed by: Rubric Capital Management LP
11/12
04:35 pm
knsa
Form 4 Kiniksa Pharmaceuticals For: Nov 07 Filed by: Levy Richard S
Low
Report
Form 4 Kiniksa Pharmaceuticals For: Nov 07 Filed by: Levy Richard S
11/8
05:32 pm
knsa
Form SC 13G Kiniksa Pharmaceuticals Filed by: BlackRock, Inc.
Low
Report
Form SC 13G Kiniksa Pharmaceuticals Filed by: BlackRock, Inc.
11/8
04:37 pm
knsa
Form 4 Kiniksa Pharmaceuticals For: Nov 06 Filed by: Patel Sanj K
Low
Report
Form 4 Kiniksa Pharmaceuticals For: Nov 06 Filed by: Patel Sanj K
11/6
04:11 pm
knsa
Form 144 Kiniksa Pharmaceuticals Filed by: Patel Sanj K
Low
Report
Form 144 Kiniksa Pharmaceuticals Filed by: Patel Sanj K
10/29
04:14 pm
knsa
Form 10-Q Kiniksa Pharmaceuticals For: Sep 30
Medium
Report
Form 10-Q Kiniksa Pharmaceuticals For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/20
Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
28.7%
3/31 Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation 26.7%
12/10 Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 18.5%
10/28 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus N/A ActVsEst N/A - N/A 11.8%
8/16 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 6.2%
3/17 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 5.7%
6/7 Form SC 13D/A Kiniksa Pharmaceuticals, Filed by: BAKER BROS. ADVISORS LP 4.4%
3/20 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.2%
8/19 Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 4.0%
1/13 Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts 3.6%
3/31 Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation 26.7%
12/10 Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 18.5%
10/28 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus N/A ActVsEst N/A - N/A 11.8%
8/16 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 6.2%
3/17 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 5.7%
6/7 Form SC 13D/A Kiniksa Pharmaceuticals, Filed by: BAKER BROS. ADVISORS LP 4.4%
3/20 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.2%
8/19 Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 4.0%
1/13 Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts 3.6%
TOP News Decliners
3/17
Form 4 Kiniksa Pharmaceuticals, For: Mar 13 Filed by: Paolini John F.
-16.6%
3/10 Form 4 Kiniksa Pharmaceuticals, For: Mar 06 Filed by: Patel Sanj K -10.4%
11/5 Form 10-Q Kiniksa Pharmaceuticals, For: Sep 30 -8.4%
6/11 Form EFFECT Kiniksa Pharmaceuticals, -8.1%
4/22 Form 4 Kiniksa Pharmaceuticals, For: Apr 20 Filed by: Beetham Thomas W. -7.1%
4/29 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.2%
2/14 Form SC 13G Kiniksa Pharmaceuticals, Filed by: AMERIPRISE FINANCIAL INC -5.6%
7/11 Form D/A Kiniksa Pharmaceuticals, -5.2%
4/1 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a $25.00 price target on the stock. -5.2%
10/16 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.9%
3/10 Form 4 Kiniksa Pharmaceuticals, For: Mar 06 Filed by: Patel Sanj K -10.4%
11/5 Form 10-Q Kiniksa Pharmaceuticals, For: Sep 30 -8.4%
6/11 Form EFFECT Kiniksa Pharmaceuticals, -8.1%
4/22 Form 4 Kiniksa Pharmaceuticals, For: Apr 20 Filed by: Beetham Thomas W. -7.1%
4/29 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.2%
2/14 Form SC 13G Kiniksa Pharmaceuticals, Filed by: AMERIPRISE FINANCIAL INC -5.6%
7/11 Form D/A Kiniksa Pharmaceuticals, -5.2%
4/1 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a $25.00 price target on the stock. -5.2%
10/16 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: